The Bristol Myers Squibb Foundation

The Bristol Myers Squibb Foundation advances health equity for disadvantaged populations around the world. 

Innovating for change

Our vision is a world where access to quality healthcare doesn’t depend on who you are or where you live. Our passion is working with our grantees to bridge the divide that separates people from equitable healthcare.

Our mission

To promote health equity and improve the health of vulnerable communities burdened by serious diseases. Our grant making empowers partners to build innovative community-based solutions to improve access to quality healthcare.

A legacy of impact

The Bristol Myers Squibb Foundation is continuing our decades long legacy of creating impact with our grantees to effect sustainable change. Together, we’re working to secure a future of equitable healthcare for all.

How we partner for change

The Bristol Myers Squibb Foundation brings together partners from the government, nonprofit, academic and private sectors to test innovations in health equity. We support programs that demonstrate the effectiveness of health system strengthening and community engagement to ensure that all patients can obtain high-quality healthcare regardless of who they are or where they live. 

We engage global experts to provide guidance and technical assistance to grantees in our therapeutic areas of focus as well as in community engagement and education, infrastructure and capacity building, healthcare provider training and much more.


Although more people today are surviving cancer, the same is not true for everyone. We are working with grantees in areas where social stigmas, inadequate education and lack of services contribute to increased mortality rates from cancers. 


We seek to improve delivery and utilization of specialty care for immunological disorders to underserved and under-resourced populations in the U.S.


We support programs that provide access to cardiology speciality medical care, social support and services for vulnerable and under-resourced populations in the U.S. to mitigate complications from cardiovascular disease.

Diversity in clinical trials

We aim to increase diversity of patients enrolled in clinical trials, expand the pipeline of diverse clinical trialists and ultimately enhance the development of therapeutics for all populations. 

Global impact

United States
  • Lung cancer 
  • Atrial fibrillation 
  • Hypertrophic cardiomyopathy
  • Rheumatoid arthritis 
  • Multiple sclerosis 
  • Diversity in clinical trials


  • Lung cancer  
  • Melanoma 


  • Lung cancer 
  • Multiple myeloma
  • Cervical cancer
  • Childhood cancers and blood disorders 
  • Lung cancer
  • Gastric cancer
  • Liver cancer